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Case presentation
A 53-yr-old woman was admitted to New England
Medical Center Hospital (NEMCH) for evaluation of pro-
teinuria and decrease in renal function. Approximately
eight to nine years earlier, the patient had developed arth-
ralgias in both ankles and hips. Several years later, she
was found to have a positive rheumatoid factor (4+), and
although joint swellings were not observed a diagnosis of
probable rheumatoid arthritis was made. Treatment with
aspirin, aeetaminophen, and indomethaein produced
some relief, but more definite improvement followed the
administration of parenteral gold salts.
Four months prior to admission at NEMCH, the pa-
tient was admitted to a local hospital where examination
revealed generalized edema, anorexia, nausea, head-
aches,fatigue, and leukopenia. Laboratory findings dis-
closed the following: white blood cell count (WBC),
1,200/mm3: hematoerit, 31% with normal indiees;platelet
count, 150,000/mm3, hut a bone marrow aspirate was un-
remarkable; serum creatinine, 1.3 mg/100 ml. Results of
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urinalysis revealed proteinuria (4+) and microscopic
hematuria; 24 hr urine protein excretion was 3.4 g. After
treatment with prednisone (20 mg/day) and furosemide.
edema disappeared, and the WBC increased to normal
levels.
Three months later, the patient was again hospitalized
for treatment of generalized edema. On admission, the
blood pressure was 180/100 mm Hg. Laboratory findings
revealed: hematoerit, 30%; WBC, 7,400/mm3; serum
ereatinine. 1.5 mg; serum albumin, 3 g/100 ml; and rheu-
matoid factor, positive (1:640). Results of urinalysis re-
vealed red blood cells and definite red blood cell casts; 24
hr urine protein excretion was 3.3 g.
One month later, the patient was admitted to NEMCH.
Medications at the time of admission included: furose-
mide. spironolactone, hydralazine. and prednisone. The
medical history revealed that Raynaud's phenomenon
had been present for many years, and that the patient had
undergone a left radical mastectomy and bilateral oopho-
reetomy ten years earlier for treatment of breast cancer.
Physical examination revealed the following: blood pres-
sure. 210/100 mm Hg; pulse. 76/mm and regular; respira-
tory rate, 12/mm; temperature, 37.5° C; atrophic, telangi-
eetatie lesions on the left hand and right elbow; arteriove-
nous nicking and narrowing in the optic fundi; and edema
(4+) in both ankles. The remainder of the examination
was unremarkable. Laboratory findings disclosed the fol-
lowing data: hematoerit, 40%; WBC, 8,400/mm3: platelet
count, 225,000/mm3; sedimentation rate, 53 mm/hr; fast-
ing blood glucose, 86 mg; blood urea nitrogen, 57 mg;
serum ereatinine, 1.5 mg; serum cholesterol, 400 mg;
serum calcium, 10.2 mg; serum phosphorus, 3.7 mg; total
serum protein, 6.8 g; serum albumin. 4.2 g; serum biliru-
bin, 0.3 mg; serum uric acid, 10.3 mg/100 ml; serum so-
dium, 140 mEq; serum chloride. 100 mEq; serum potas-
sium, 4.0 mEq; and total carbon dioxide, 29 mEq/liter;
alkaline phosphatase. 1.2 Bodansky U; antinuclear anti-
body. negative; antidouble-stranded DNA, negative;
rheumatoid factor, positive (1:320): total hemolytie com-
plement, 75 mg/100 ml. Results of urinalysis revealed:
pH, 5.5; protein, 3+; blood, 1+: urine sediment, multiple
red blood cells and several white blood cells/high power
field; definite red cell casts: 24 hr urine protein excretion,
5.2 g; urine culture revealed mixed skin flora in low cob-
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fly counts. Chest x-ray films revealed cardiomegaly with
left ventricular prominence. EKG revealed sinus rhythm
with an axis of 400, and left ventricular hypertrophy by
voltage criteria.
The patient's hypertension was treated with alpha-
methyldopa. Serum creatinine concentration remained
stable at approximately 1.5 to 1.6 mgIlOO ml during the
first week of hospitalization. Ten days after admission, a
closed kidney biopsy was performed.
Some data, which became available later in the pa-
tient's course, have not been included in this presenta-
tion, but will be provided when requested by the dis-
cussant in order to simulate the original diagnostic prob-
lem.
Discussion
Dg. R. J. GLASSOCK: This case is indeed a per-
plexing one, no doubt culled from the archives of
challenging problems encountered at this hospital.
To briefly recapitulate, a 53-yr-old woman in-
sidiously developed heavy proteinuria and edema
accompanied by mild hypertension, moderate im-
pairment of renal function, and an active urinary
sediment including red blood cell casts. Decreased
serum albumin concentration, increased serum cho-
lesterol concentration, and decreased serum total
hemolytic complement activity (HCA) were docu-
mented. Renal disease developed on a background
of a long standing illness believed to be rheumatoid
arthritis (RA), characterized at one time by sym-
metrical ankle and hip arthralgias, Raynaud's phe-
nomenon, atrophic and telangiectatic skin lesions,
anemia, leukopenia, and a positive rheumatoid fac-
tor. Immunofluorescent assay for antinuclear anti-
bodies and radioimmunoassay for antibody to
double-stranded DNA (dsDNA) were negative.
Many years previously, she had received chryso-
therapy and had a breast removed for carcinoma.
On admission, there was no evidence of recurrent
cancer.
The patient's current problem focuses on one of
the cardinal manifestations of glomerular disease,
i.e., nephrotic syndrome (NS). As is universally
recognized, heavy proteinuria results from some
disturbance of the barrier function of the glomerular
capillary wall, which normally prevents passage of
serum proteins into Bowman's space and thence in-
to the urine. The recognition in recent years of an
important role for both the anatomic integrity and
the charge of various molecules present in the gb-
merular capillary wall has provided new insights in-
to the possible mechanisms underlying the distur-
bances in glomerular function that result in protein-
uria [I].
The disorders that evoke heavy proteinuria,
whether accompanied by a mild decrease in serum
albumin concentration or not, may be divided caus-
ally into two very broad categories: first, those
forms associated with some underlying disease (of-
ten of an infectious, metabolic, hereditary, or multi-
system nature) or with drug exposure; and second,
those forms in which the kidney alone is involved,
i.e., the so-called primary or idiopathic nephrotic
syndrome [2]. Clearly, the disorder of the patient
described here has many features that suggest classi-
fication into the former category, but it is remotely
possible that her glomerular disease is a chance oc-
currence and unrelated to the pre-existing chronic
illness. In any event, evaluation of this patient from
the point of view of secondary NS seems to be a
logical first step. At this point, it would be appropri-
ate to review the pertinent x-ray findings.
DR. J. T. HARRINGTON: X-ray films of the joints
were considered to be normal, and the i.v. urogram
was unremarkable.
DR. R. J. GLASSOCK: In view of the clinical find-
ings in this patient, the discussion might be initiated
by considering whether or not the patient has RA,
and, if so, What is the possible relationship between
RA and renal disease? Insufficient criteria are pres-
ent to establish the patient's disease as classical or
definite RA although 4 of the II criteria proposed by
the American Rheumatism Association are present,
which would categorize her disease as probable RA
[31. Although joint involvement was symmetrical,
there was little tendency for involvement of the
proximal joints of the hands and wrists, little or no
deformities were present, no swelling of the joints
were actually observed by a physician, and most
importantly x-ray films failed to reveal the typical
erosive changes of classical RA. A positive rheuma-
toid factor (RF) may occur in other connective tis-
sue and infectious diseases although the titer in this
case was well within the range seen in patients with
RA. Development of leukopenia might suggest Fel-
ty's syndrome; the spleen was not enlarged, how-
ever, and the bone marrow did not reveal increased
granubocytopoiesis. The patient's anemia was prob-
ably due to chronic illness, and insufficient informa-
tion is provided to decide whether or not occult
hemolysis or a microangiopathic process was oc-
curring. The prominent history of Raynaud's phe-
nomenon is interesting, and although this finding
may be present in patients with classical RA it is
usually not found as a prominent symptom. In many
patients with RA, Raynaud's phenomenon may be
due to an underlying small vessel vasculitis. De-
creased total HCA is not observed in uncompli-
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cated RA. In fact, as shown by Ruddy and Austen
[41, HCA and individual complement (C) proteins
(primarily C3) are usually modestly increased in un-
complicated RA. Total HCA may be decreased in
those varieties of RA associated with an inherited
deficiency of complement components, such as C2
deficiency, or in the presence of disseminated vas-
culitis ("malignant" rheumatoid disease) [5, 6]. The
kidney in RA has been the subject of several inves-
tigations over the past several decades [7—121. Ren-
al lesions observed in RA include the following: am-
yloidosis, chronic interstitial nephritis, arteriolar
nephrosclerosis, fibrinoid necrotizing vasculitis,
membranous glomerulopathy arising as a complica-
tion of therapy with either gold or penicillamine,
glomerular lesions resembling those found in sys-
temic lupus erythematosus (SLE), and "rheuma-
toid glomerulitis" representing a diffuse or segmen-
tal increase in endothelial cell nuclei [7—121.
Let us consider amyloidosis first, Secondary am-
yloidosis is the most common renal disease of clini-
cal significance occurring in patients with long-
standing RA, second only to the complications of
chrysotherapy and penicillamine. The overall prev-
alence of amyloidosis in patients with RA is difficult
to estimate because most pathologic studies are
done on relatively selected populations. In an au-
topsy series reported some years ago, as many as
60% of patients with RA were found to have patho-
logic evidence of amyloidosis [131. There were few
clinical manifestations of amyloidosis in many of
these patients. Perhaps the best estimate of the fre-
quency of clinically significant amyloidosis in pa-
tients with RA comes from biopsy series in which
the prevalence is approximately 10 to 15% [9, 10].
Even though amyloidosis is the most common
cause of NS in patients with classical RA, several
features present in this patient make it difficult to
accept a diagnosis of amyloidosis. First, an active
urinary sediment, particularly red blood cell casts,
is not typical of amyloidosis. Second, the decrease
in total HCA is not typically seen in amyloidosis.
Third, cardiac findings in this patient were more
suggestive of hypertensive cardiovascular disease
than amyloidosis. Fourth, hypertension usually is
not seen in amyloidosis unless significant azotemia
has developed.
A possible relationship of gold therapy to the re-
nal lesion should be briefly examined. Abnormal
proteinuria, often in the nephrotic range, occurs in
approximately 5 to 7% of patients receiving gold
therapy for RA [14—161. Other manifestations of
gold toxicity include dermatitis, hematuria, mild
azotemia, and leukopenia. Nephrotic syndrome
usually occurs in close proximity to the administra-
tion of gold, but it is not strictly a dose-related phe-
nomenon. The renal lesions encountered are com-
monly those of membranous glomerulopathy with
heavy granular deposits of immunoglobulins and
subepithelial deposits seen by immunofluorescence
and electron microscopy, respectively [17, 18]. The
lesions often subside when gold therapy is discon-
tinued. It is not well understood why this agent has
such a propensity to evoke glomerular lesions. One
postulate is that gold has the capacity to bind to tis-
sue proteins, perhaps derived from the kidney it-
self, and thus induces a subtle alteration in the im-
munogenicity of autologous tissue proteins. The re-
sulting immune response may lead to the formation
of circulating immune complexes (IC), which may
preferentially deposit in the glomerular capillary
circulation and evoke membranous glomerulo-
pathy. Several investigators have searched for au-
tologous antigens of renal tubular epithelial origin in
the capillary wall deposits of membranous nephrop-
athy in patients treated with gold, but no such auto!-
ogous antigen has as yet been identified [191. Pen-
icillamine, another agent used in the treatment of
RA, has also been noted to produce NS with immu-
nopathologic evidence of glomerular deposition of
IC [201. The temporal relationships between gold
therapy and the development of NS in this patient,
however, make it unlikely that the two were re-
lated.
Several other entities can be dismissed readily.
Chronic interstitial nephritis may be associated with
mild abnormalities of renal function or, on occa-
sion, sterile pyuria. Nephrotic syndrome would not
be expected to occur in the absence of obstruction
or vesicoureteric reflux. Arteriolar nephrosclerosis
appears to be a rather nonspecific finding in RA,
perhaps related to the patient's age. No convincing
evidence of a specific rheumatoid vasculopathy,
other than that associated with "malignant" rheu-
matoid disease, has been reported. "Malignant"
rheumatoid disease with fibrinoid necrotizing vas-
culitis is often associated with extremely high RF
levels, subcutaneous nodules, serositis, pen-
carditis, neuropathy, fever, ischemic ulcers, and
abdominal pain [6, 211. Occasionally, there may be
associated proteinuria, but for reasons not well un-
derstood the kidney is seldom involved in rheuma-
toid vasculitis despite strong evidence implicating
circulating IC in the pathogenesis of the vascular
lesions [221. Complement levels may be reduced,
and muscle biopsies reveal small vessel vasculitis
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[6, 211. Renal lesions, when present, are typically
fibrinoid necrotizing vasculitis and are sometimes
accompanied by severe hypertension, but seldom
by NS [23, 241.
We should now turn to a consideration of the dis-
order that represents the most likely explanation for
the patient's renal disease; namely, SLE. Renal in-
volvement is common, if not a universal occur-
rence, in SLE [2]. The long-standing history of ar-
thralgia with little or no joint deformities or erosions,
Raynaud's phenomenon, telangiectatic skin lesions,
positive RF, leukopenia and anemia, active urinary
sediment, NS, and decreased serum HCA are all
consistent with the diagnosis of SLE [25]. The fluo-
rescent antinuclear antibody (ANA) test and assays
for antibody to dsDNA, however, were negative.
Even though the patient was receiving low-dose
prednisone therapy at the time these assays were
performed, it would be unusual for a patient with
SLE who is manifesting this degree of renal abnor-
malities and exhibiting decreased HCA to have un-
detectable levels of ANA or antibody to dsDNA.
Most published series indicate that about 10% or
less of patients with untreated SLE and active renal
disease have negative ANA [26—29]. One possible
explanation for these findings is that patients devel-
oping circulating free DNA may bind all available
antiDNA antibody in the form of circulating IC.
Treatment of the serum of such patients with
DNAase might unmask the "hidden" ANA [30]. In
recent studies by Tron and Bach [26, 27], nearly
every patient with SLE and active renal disease had
significantly elevated levels of antibody to dsDNA.
In addition, patients with active renal or systemic
disease in SLE would be expected to have positive
tests for circulating IC [31], and on occasion these
IC acquire the property of insolubility at cold tem-
peratures. Thus, cryoglobulinemia may be a promi-
nent feature of SLE [32]. These circulating IC may
also be detected by a variety of newly described
methods, such as the Clq binding assays [33, 34],
Raji cell radioimmunoassay [35], and the inhibition
of agglutination of immunoglobulin-coated latex
particles by Clq or RF [36, 37]. It would be inter-
esting to know if this patient had circulating IC or
cryoglobulins.
Thus, in the absence of highly specific serologic
evidence for SLE and despite the existence of mul-
tiple clinical criteria supporting this diagnosis, it is
rather difficult to sustain an unequivocal diagnosis
of SLE. Skin biopsy might be helpful since patients
with SLE have been found to have dermal-epider-
ma! junctional deposits of immunoglobulins and C
even if the skin is not obviously involved [381.
DR. V. W. PINN (NEMCH): We do have the re-
sults of a biopsy of two areas of skin from the right
arm. The specimen from a noninvolved area was
normal by light microscopy, and there was no evi-
dence of immunoglobulin (IgG, 1gM, or IgA), C (C3
or c4), or fibrinogen deposition in this biopsy by
immunoflourescent studies. The biopsy from an
"involved" area showed focal collagen degenera-
tion, foci of degenerating epidermal cells and mild
perivascular chronic inflammation, but a specific
diagnosis could not be established. Immuno-
flourescent studies on this biopsy failed to demon-
strate deposition of IgG, 1gM, IgA, or C (C3, C4);
there was focal granular deposition of fibrinogen,
however, at the dermal-epidermal junction.
DR. R. J. GLASSOCK: Thus, the skin biopsy find-
ings do not lend any further support to a diagnosis
of SLE. Let us now consider the possibility of
mixed connective tissue disease (CTD). This dis-
order is suggested by the presence of very promi-
nent symptoms of Raynaud's phenomenon, arthri-
tis, fatigue, and telangiectatic skin lesions [39]. The
absence of a high titer speckled pattern on fluores-
cent ANA testing and the presence of decreased
HCA, however, make this diagnosis quite unlikely
[39]. The ANA test in this case was performed using
mouse liver nuclei as the substrate. This is an im-
portant point because some laboratories perform
fluorescent ANA tests on substrates that might not
detect the presence of certain antinuclear factors,
particularly antibody to the extractable nuclear an-
tigen, which is commonly, if not invariably, found
in mixed CTD. It is possible that if the laboratory
used a DNA spot test as the nuclear substrate the
test might not detect the antibody to the saline ex-
tractable, RNAase sensitive nuclear antigen that is
so characteristic of mixed CTD.
DR. V. AGNELLO (NEMCH): One can occasion-
ally find a negative ANA in the presence of anti-
bodies to the saline extractable nuclear antigens,
Sm or RNA protein, that are detectable by hemag-
glutination [40]. We looked specifically for Sm and
RNA protein antibodies using the hemagglutination
technique, and none were present.
DR. R. J. GLASSOCK: The serological findings
thus virtually exclude the possibility of mixed CTD
even though certain of the clinical features suggest
this diagnosis. Renal disease with glomerular in-
volvement is a rather uncommon finding in mixed
CTD. Sharpe et al [41] have found that only about
10% of patients with mixed CTD ultimately develop
some form of glomerular disease. Of the reported
cases of mixed CTD in which there has been gb-
merular involvement, about two-thirds have shown
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membranous glomerulopathy, a disorder that is not
characterized by reduction in total HCA [42, 43].
It would be appropriate to discuss other dis-
orders, which may at times be complicated by renal
disease. Patients with essential, mixed (IgG/IgM)
cryoimmunoglobulinemia (GIG) may present with
arthralgias and positive RF [44, 45]. The RF titer
may be markedly elevated in patients with CIG who
develop progressive renal disease. These patients
also typically have markedly depressed serum C
concentrations, including Clq, C4, and C3 146]. It is
difficult to sustain a diagnosis of classical CIG in
this patient since purpura was not observed at any
time and the spleen and liver were not enlarged,
both of which are characteristic findings in this syn-
drome. As mentioned earlier in the context of the
diagnosis of SLE, it would be worthwhile to search
for cryoimmunoglobulins in this patient and if pres-
ent to analyze their biochemical composition fur-
ther. On occasion, these cryoimmunoglobulins will
contain hepatitis B antigens or antibody to the hepa-
titis B surface antigen [47].
DR. J. T. HARRINOTON: The concentration of
cryoprecipitates in this patient was 0.505 mg/mI; the
normal value is less than 0.1.
DR. R. J. GLASSOCK: The cryoprecipitates dem-
onstrated in this patient might for the moment be
assumed to be composed of immunoglobulins and
an unidentified antigen, i.e., an immune complex.
Such cryoglobulinemia is not an uncommon finding
in many forms of glomerulonephritis including SLE
[48]. Do you have the results of a hepatitis B surface
antigen assay?
DR. J. T. HARRINCTON: It was negative.
DR. R. J. GLASSOCK: In view of the abnormal to-
tal HCA found in this patient, it is relevant to dis-
cuss the possibility that an inherited C deficiency
state might underlie her present disease. As has
been well described by Agnello [5], patients with a
variety of hereditary C deficiency states may de-
velop CTD with features that often overlap those of
RA, SLE, and scleroderma. The frequency of typi-
cal and atypical SLE is greatly increased in patients
who are both homozygous and heterozygous for C
deficiency [49, 50]. Among the approximately 60
cases of hereditary C deficiency thus far reported,
at least 24 had some variety of CTD, predominantly
SLE or an SLE-like syndrome [5]. Deficiency of C2
is the most common and best studied of the C defi-
ciency states. In reference to the patient described
here, it is worth noting that heterozygous individ-
uals with C2 deficiency have reduced but not absent
C2 levels, and the HCA may be approximately 50%
of normal. Dr. Agnello, has this been your general
experience with heterozygous patients?
DR. V. AGNELLO: Yes, it has.
DR. R. J. GLASSOCK: Several adults with hetero-
zygous C2 deficiency have been described with var-
ious manifestations including SLE and other SLE-
like diseases [5]. The particular features of C2 defi-
ciency associated with these disorders are: (1) an
increased prevalence of discoid LE lesions; (2) a
tendency for the formation of small amounts of anti-
body to DNA; (3) a low titer and in a few instances
even negative ANA; and (4) a low prevalence of
renal disease. The precise mechanisms underlying
the relationship of various types of C deficiency
states to the development of autoimmune (AT) dis-
ease is unknown. One possibility is that genes that
regulate the serum concentration of various C pro-
teins are linked to other genes that determine the
susceptibility to Al or CTD [5]. The genes that regu-
late the serum concentration of C2, C4, and Factor
B are located within the major HLA complex [51].
Most patients with hereditary C2 deficiency, for ex-
ample, have the HLA-haplotype AlO, Bl8, and
DW2 [5]. Another possible link between C defi-
ciency states and A! or CTD is that an impaired C
cascade may interfere with the processing of a vari-
ety of exogenous materials, particularly viruses
[52]. For example, Cooper et al [53] have demon-
strated that certain C proteins, particularly C4, are
involved in the lysis of viruses in the absence of
antibody. Thus, the complement cascade may be a
very primitive biological defense system. If this sys-
tem is defective and viruses are permitted to repli-
cate in the presence of a modulated humoral re-
sponse, then circulating IC might develop, persist in
the circulation, and deposit in various vascular
structures leading to the manifestations of CTD.
Except for the fact that this patient presented
with prominent manifestations of renal disease,
many of her clinical features suggest the possibility
of an underlying C deficiency state. Were concen-
trations of Clq, C4, and C3 measured?
DR. J. T. HARRINGTON: The patient's C values
were as follows: Clq, 0.105; C4, 0.008; and C3, 0.5.
All of these values are below normal.
DR. R. J. GLASSOCK: These results clarify consid-
erably the nature of the decrease in total HCA.
They also reemphasize the point that many investi-
gators have made; that is, the HCA is a useful test
in screening for the presence of abnormalities of the
C sequence and may be helpful in understanding
some of the variants of SLE and RA. This patient
has a prominently decreased C4 and C3 and a some-
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what decreased Clq concentration in serum. This
pattern is suggestive of circulating IC activating the
classical sequence of C activation as might be found
in SLE; this pattern is not suggestive of an inherited
C deficiency state. A decrease in the concentration
of C4 is seen in other IC diseases, yet it is inter-
esting that some patients with SLE may have only
modest decreases in the concentration of C3 but a
pronounced decrease in C4 concentration. It is for
this reason that many rheumatologists have pre-
ferred C4 concentrations as a monitoring test for
following the course of patients with SLE. The
serum concentration of C4 also seems to correlate
best with the presence and severity of renal disease
[54].
Finally, because of the history of carcinoma of
the breast in this patient it is worth mentioning that
a variety of malignancies have been associated with
glomerulopathies, including those that may provoke
the NS. Of 171 patients with NS associated with
malignancy recently reviewed by Eagan and Lewis
[55], 67 had an underlying carcinoma; 86 had under-
lying Hodgkin's disease or nonHodgkin's lym-
phoma, leukemia or Waldenstrom' s macroglobulin-
enlia; 12 had embryonal cell tumors; and 6 had be-
nign solid tumors. Only 2 of the 67 patients with
underlying carcinoma had carcinoma of the breast.
Over 80% of the patients developed NS within 12
months of the time of diagnosis of cancer. Mem-
branous glomerulopathy was the principal lesion
observed in patients developing NS in association
with carcinoma. The interval between the develop-
ment of cancer of the breast and the development of
renal disease in this patient makes a relationship of
these two events remote.
Could the development of glomerular disease in
this patient be a chance occurrence unrelated to her
underlying CTD, and if so what might be its likely
nature? Nephrotic syndrome resulting from primary
glomerular disease may be categorized on the basis
of correlative light, immunofluorescent, and elec-
tron microscopic studies in several forms: (1) mini-
mal change disease (MCD); (2) focal and segmental
glomerulosclerosis (GS) with hyalinosis; (3) mem-
branous glomerulopathy (MG); and (4) various pro-
liferative lesions, the most prevalent of which is
membranoproliferative glomerulonephritis (MPGN)
[2]. The clinical differentiation of these lesions
based upon common clinical criteria, such as blood
pressure, renal function, urinalysis, and protein ex-
cretion rates, is quite unreliable. Minimal change
disease is most frequently associated with a benign
urinary sediment, normal renal function, normal
diastolic blood pressure, and a strikingly elevated
serum cholesterol. It is important, however, to em-
phasize that microhematuria may be present in up
to 20% of patients with MCD. There is a tendency
for highly selective proteinuria to occur in MCD,
but exceptions to this rule occur especially in
adults. This lesion is most commonly encountered
in children, but may also be found in 10 to 15% of
adults with idiopathic NS. Focal and segmental GS
with hyalinosis is often associated with the develop-
ment of hypertension, abnormal glomerular filtration
rate (GFR), sterile pyuria and hematuria, and defects
of renal tubular function. There is also a tendency
for poorly selective proteinuria. This lesion is found
in approximately 10 to 15% of adults with idiopathic
NS. Membranous glomerulopathy is a slowly evolv-
ing disease, and the development of abnormal GFR
a few months after the apparent onset of disease is
unusual. Similarly, an active urinary sediment is un-
common unless the patient has developed a very rare
complication of antiglomerular basement mem-
brane antibody disease superimposed on chronic in-
dolent MG [56]. As is well known, MG may com-
plicate a variety of diseases including cancer, SLE,
and drug exposure such as gold and penicillamine
[2]. Most importantly the HCA is expected to be
normal in MCD, focal GS, and MG. Hemolytic
complement activity is often, but not invariably, re-
duced at some point in time during the course of
patients with MPGN [57]. Membranoproliferative
glomerulonephritis is associated with the clinical
findings of NS, mild hypertension, modestly im-
paired GFR, and active urinary sediment. This dis-
order is now recognized to be an extremely hetero-
geneous group of clinicopathologic entities. Light
microscopic studies reveal that MPGN is character-
ized by proliferation of mesangial cells, and an ex-
tension of these cells and cytoplasm into the periph-
ery of the glomerular capillary loops leading to a
thickened and reduplicated appearance of the capil-
lary wall. Variable degrees of increased mesangial
matrix may also occur. Electron microscopic stud-
ies reveal several distinctive categories of MPGN.
These fall predominantly into two major groups,
type I revealing extensive subendothelial electron
dense deposits in the glomeruli and type II reveal-
ing intramembranous electron dense transformation
(so called dense deposit disease") [58]. Several
additional ultrastructural variants have recently
been described [59—61]. The immunofluorescent ap-
pearance of these two lesions differ as do the pat-
terns of serum C component concentrations. For
example, type I MPGN often reveals immunoglobu-
1;
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un deposition in a granular pattern along the capilla-
ry loops in association with C3. There may also be
associated deposition of the early acting components
of C; namely, Clq and C4 [62]. Serum concentration
of C3 tends to be depressed although wide fluctua-
tions may occur from time to time. Early acting C
components in the serum may be normal or de-
creased [63]. This type of MPGN may occur in an
idiopathic fashion or may be associated with dis-
eases such as SLE, chronic hepatitis B antigen-
emia, and a variety of other chronic infectious dis-
eases [2]. On the other hand, type II MPGN reveals
absent or scanty immunoglobulin deposition, prom-
inent C3 deposition in both the mesangium and in
the peripheral capillaries, and absent early acting C
component deposition [62]. Serum C3 concentra-
tion is uniformly decreased, and the early acting C
components are usually normal [63]. Furthermore,
a factor capable of cleaving native C3 in vitro is of-
ten found in the serum of such patients. This factor,
called C3 nephritic factor (C3NeF), has recently
been found to be an autoantibody to the C3 convert-
ase of the alternative pathway of C activation [64,
65]. This antibody apparently stabilizes and pro-
tects the enzymatic activity of alternative pathway
C3 convertase, allowing for enhanced C3 cleavage
in vivo and in vitro.
It would seem quite likely that the glomerular dis-
ease in the patient presented here is in fact related
to the underlying CTD rather than being the chance
occurrence of a separate condition. I am uncertain
however about the true nature of the basic disease
process present in this patient. It would appear that
it falls into the general category of CTD and perhaps
represents one of the variants of SLE. I am con-
fident that the renal biopsy will reveal a prolifera-
tive glomerulonephritis, most likely of the mem-
branoproliferative category. This conclusion is
based largely on the findings of an active urinary
sediment, NS, mild impairment of the GFR, and
prominent reduction of C components including C3.
The electron microscopic studies will likely reveal
subendothelial deposits, and I would not be sur-
prised if the immunofluorescent findings are positive
for both immunoglobulins and C, C3 as well as the
early acting components. The role of the cryopre-
cipitates found in this patient and the genesis of the
renal lesion are unclear. Such cryoprecipitates may
in fact represent the same species of IC that have
deposited in the glomerular capillaries and evoked
the manifestations of proteinuria, impaired GFR,
and hematuria.
Pathologic presentation
Dr. J. T. HARRINGTON: Dr. Pinn will review the
biopsy findings.
DR. V. W, PINN: A percutaneous biopsy of the
kidney was examined and found to demonstrate a
diffuse glomerulonephritis. The glomeruli were
swollen and hypercellular with proliferative and ex-
udative changes. There was predominantly mesang-
ial matrix increase with mesangial cell proliferation
(Fig. 1). Foci of thickened peripheral glomerular
capillary basement membranes were identified with
areas on the silver stain suggestive of reduplicated
basement membrane material. Other than some
mild thickening of vessel walls, there was no promi-
nent vascular disease, and no evidence of a vascu-
litic process could be identified. Ultrastructural
analysis of the glomeruli revealed expanded mesan-
gium with increased mesangial matrix and cellula-
rity. Endocapillary proliferation and frequent poly-
morphonuclear leukocytes were noted within gb-
merular capillary lumena. Scattered electron dense
deposits were identified in subendothelial (Fig. 2),
subepithelial, and intramembranous locations.
These deposits did not have the typical fibrillar ul-
trastructural morphology that has been described
for cryogbobulins [66]. Localized splitting of the gb-
merular basement membrane was present as well as
extensive glomerular epithelial cell foot process fu-
sion.
Immunofluorescent studies demonstrated trace to
1 + (on a 4+ scale) finely granular to segmental lin-
ear deposition of IgG and fibrinogen in a peripheral
pattern along glomerular capillary basement mem-
branes. There were more prominent (1+ to 2+) de-
posits of 1gM and C (C3) in a similar pattern (Fig. 3).
Fig. 1. Glo,neruli ii'ith expanded inesangium and /zvper—
cellularity. PAS. x 145.
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Fig. 2. Portion of a glomerulus showing subendothelial electron
dense deposits along one capillary basement membrane (arrow)
and polymorphonuclear leukocytes in capillary lumens. Electron
microscopy, >< 5200.
Stains for IgA, albumin, and other components of C
(C4 and Clq) were negative.
Our diagnosis, on the basis of the findings from
the biopsy material, is MPGN, type I.
Dr. R. J. GLASSOCK: The absence of Clq and C4
in the glomerular deposits is worth commenting up-
on. In my experience, patients with proven SLE
and MPGN nearly always have positive Clq and C4
in addition to C3 deposits in the renal biopsy.
DR. V. AGNELLO: Our experience is somewhat
different. With the reagents that we are using, we
find less Clq than C3 in typical biopsies from pa-
tients with SLE.
Fig. 3. Immunofluorescent demonstration of finely granular to
segmental linear deposits of complement ((3) along glomerular
capillary basement membranes (>< 365).
DR. R. J. GLASSOCK: I am still troubled by the
diagnosis of classical SLE. Even though the other
clinical criteria definitely point in that direction, the
negative skin biopsy and the serological non-
reactivity in the face of active renal disease make it
difficult to sustain that diagnosis. It would be partic-
ularly useful in patients such as this to isolate the
cryoprecipitate and analyze it for the presence of
immunoglobulins, C, DNA and, anti-DNA antibody.
In a few instances, it has been possible to identify
the nature of the circulating IC in SLE, and, as has
been suspected, the major IC systems participating
in this disease appear to be composed of DNA and
anti-DNA [67].
DR. J. T. HARRINGTON: Dr. Agnello, can you ex-
plain the discrepancy between the history, which is
strongly suggestive of SLE, and the lack of sero-
logic evidence for this disease?
DR. V. AGNELLO: I think this is a most atypical
case and is reminiscent of a case we reported some
time ago [68]. As Dr. Glassock very astutely point-
ed out, it is now apparent that there is a small per-
centage of patients with SLE who have negative
ANA. My feeling is that this patient's disorder falls
into the broad range of SLE in terms of current cri-
teria. My bias is that in classical SLE you always
see antibodies to dsDNA sometime in the course of
the disease. Thus, strictly speaking this is not clas-
sical SLE, but it is, I think, atypical SLE. The test
for native DNA antibody was negative, but the pa-
tient had a very high titer of antibodies to the single-
stranded DNA (ssDNA). This also points out that
with high titer ssDNA antibody the ANA may be
negative because there is no ssDNA in the nucleus
in the resting state of the cell. We know that anti-
bodies to ssDNA have been implicated in the renal
lesion of SLE, so at least one potentially pathologic
population of autoantibodies is present. We did
look at the cryoprecipitates in this patient. My feel-
ing is that the cryoprecipitate is probably playing a
role in the nephritic process. We isolated the
cryoprecipitate, and it was a mixed cryoglobulin.
We did exactly what you suggested, which was to
fractionate the cryoprecipitate into IgG and 1gM
and look for specific antibodies. There were no anti-
bodies to native DNA, nor was there positive anti-
nuclear reaction in either of the fractions. But the
1gM was a monoclonal RF, and this is very similar
to the findings in the initial patient that I mentioned.
We have seen several SLE patients with mixed
cryoglobulins and nephritis in whom the renal le-
sion behaved in a fashion similar to that in this pa-
538 Nephrology Forum
tient. That is, there was a relatively rapid onset of
azotemia, which is relatively rare in SLE. The first
patient that we described with SLE and mixed
cryoglobulinemia also had a negative ANA and a
negative dsDNA, but IC containing a monoclonal
RF could be demonstrated in the circulation. The
fluorescent studies on the renal biopsy in this pa-
tient were particularly interesting in that the 1gM
glomerular deposits, as in the patient described
today, were heavier than the IgG deposits, which is
a reverse of the situation usually seen in SLE. With
regard to the C studies, it is our experience, and
that of others, that in SLE nephritis C3 is pre-
dominantly present with lesser amounts of Clq.
Thus, I think the findings in this patient are most
consistent with glomerulonephritis associated with
the mixed cryoglobulinemia of SLE.
DR. R. J. GLASSOCK: Dr. Agnello, would you ex-
pect antibodies to ssDNA to be detected by a tech-
nique that uses leukocyte nuclei from huffy coat as
a substrate as opposed to those that employ mouse
liver as the substrate? We have observed positive
antinuclear antibody in the fluorescent antibody as-
say using human kidney as the substrate in patients
who had ssDNA antibodies. Of course, most of
them had antibody to dsDNA also.
DR. V. AGNELLO: It would depend on how the
cells were handled. One might find denatured DNA
in the nuclei if the cells were not fixed properly [69].
DR. R. J. GLASSOCK: In the final analysis, this un-
usual case amply demonstrates the multitude of an-
tigen/antibody systems that may operate in the pro-
duction of renal lesions in the connective tissue
group of diseases, in particular SLE. Glomerular
capillary deposition of IC composed of dsDNA,
ssDNA, ribonucleoprotein, lymphocyte surface an-
tigens, erythrocyte antigens, retroviral antigens, au-
tologous IgG and their respective antibodies may
each participate in the production of glomerulone-
phritis in this disease.
Questions and Answers
DR. J. P. KASSIRER: There is certainly little expe-
rience with patients who have a variant of SLE with
mixed cryoglobulinemia and type I MPGN, but we
must nevertheless make a therapeutic decision. At
the time of the biopsy, this patient's serum creati-
nine concentration was 1.5 mg/100 ml, the urine
sediment was active, and proteinuria was heavy. In
addition, the serum C concentration was reduced,
and mixed cryoglobulins were present in increased
concentrations. How would you proceed with treat-
ment?
DR. J. J. COHEN: Before you answer, let me pose
this question: If there were some means of deter-
mining whether the patient had idiopathic type I
MPGN as opposed to the same lesion occurring as a
complication of SLE, would you treat the patient
differently?
DR. R. J. GLASSOCK: The experience with steroid
and immunosuppressive therapy in idiopathic type
I MPGN has been rather disappointing. One uncon-
trolled study in children, however, has reported a
beneficial effect of moderate doses of alternate day
steroids given over long periods of time [70]. As-
suming we are dealing with a variant of SLE, an
aggressive approach to treatment would likely be
beneficial, although admittedly this is a con-
troversial point [7 1—73]. One might choose between
treatment with high-dose steroid therapy given for a
short period of time, approximately three to six
months, or moderate-dose, alternate day steroid
therapy supplemented by a cytotoxic agent. This
approach to treatment is likely to be more beneficial
in MPGN due to SLE or in association with CIG
than in idiopathic MPGN. The presence of cryopre-
cipitates also brings up the question of intensive
plasma exchange. Although the use of intensive
plasma exchange in the treatment of glomerulone-
phritis has not yet been evaluated in a controlled
clinical trial, there is preliminary evidence that pa-
tients with SLE and other patients with progressive
renal disease who exhibit high levels of circulating
IC or cryoglobulins or both may benefit from such
treatment [74]. How was the patient treated, Dr.
Harrington?
DR. J. T. HARRINGTON: Initially, the patient was
treated with only prednisone and cyclophospha-
mide; plasmapheresis was not carried out. When
she was seen 1 month after discharge, the C3 con-
centration had increased to 0.96. The cryoprecipi-
tates had decreased from the initial value of 0.51 to
0.23 after 1 month and to 0.14 after 2 months of
prednisone and cyclophosphamide therapy. Her
renal function and protein excretion did not change
during this period. Plasmapheresis was carried out
later, first, to isolate and identify the cryoprecipi-
tate and, second, in the hope that it might be helpful
therapeutically. With a 2-liter large volume plas-
mapheresis, cryoprecipitates dropped further to
0.06, but there were no obvious clinical con-
sequences of this treatment.
DR. J. P. KASSIRER: What are your thoughts
about using the combination of prednisone and cy-
clophosphamide?
DR. R. J. GLASSOCK: With regard to the use of
cyclophosphamide, I am becoming more and more
concerned about the increasing number of reports
indicating the development of leukemia in patients
who have received long-term cyclophosphamide for
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nonneoplastic diseases [75]. The data in the litera-
ture does not permit one to make a rational choice
among alkylating agents, such as cyclophospha-
mide, chlorambucil, or azathioprine. In fact, the
overall usefulness of any of these agents given in
conjunction with steroids in patients with proven
SLE and diffuse proliferative glomerulonephritis
has not been demonstrated unequivocally in a long-
term controlled clinical trial [76].
Reprint requests to Dr. RichardJ. Glassock, Division of Nephro-
logy, Harbor General Hospital, Torrance, California 90509,
U.S.A.
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